首页 > 最新文献

JHEP Reports最新文献

英文 中文
Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score MASLD、MetALD 和 ALD 患者的特征和长期死亡率以及 SAFE 评分的实用性
IF 9.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-03 DOI: 10.1016/j.jhepr.2024.101127

Background & Aims

The new nomenclature of steatotic liver disease (SLD) was recently launched with sub-classifications of metabolic dysfunction-associated SLD (MASLD), MASLD with increased alcohol intake (MetALD), and alcohol-related liver disease (ALD). Herein, we aimed to evaluate the characteristics and long-term outcomes associated with these subgroups and the utility of non-invasive biomarkers.

Methods

Using NHANES III (the third National Health and Nutrition Examination Survey) and linked mortality data, all adult participants with available ultrasonographic liver steatosis status were included. Those with viral hepatitis, incomplete data on alcohol consumption, cardiometabolic risk, and missing data that hindered Steatosis-associated Fibrosis Estimator (SAFE) score calculation were excluded. The characteristics of those without SLD (no steatosis on ultrasound), MASLD, MetALD, and ALD were compared. Overall survival (OS) was determined and SAFE score strata were applied to SLD subgroups.

Results

A total of 9,939 participants were eligible; 64% had no SLD, while 30%, 2.3%, and 1% had MASLD, MetALD, and ALD, respectively. A higher proportion of men, as well as active smokers, was observed in the MetALD and ALD groups compared to the MASLD group. Diabetes was more prevalent in the MASLD group than in the MetALD and ALD groups. The ALD subgroup had significantly lower OS than the MASLD group (p = 0.004), but the MetALD did not (p = 0.165). SAFE score strata meaningfully differentiated OS of all SLD subgroups.

Conclusions

MASLD accounted for the largest proportion of SLD. MetALD shared the characteristics of both MASLD and ALD. The ALD subgroup had a significantly lower OS than the MASLD subgroup but there was no difference between MetALD and MASLD. The SAFE score can be used to stratify long-term outcomes in all SLD subgroups.

Impact and implications:

“Steatotic liver disease (SLD)” is a recently introduced term covering three subgroups: MASLD (metabolic dysfunction-associated SLD), MetALD (MASLD with increased alcohol intake), and ALD (alcohol-related liver disease). We explored the characteristics and outcomes of these subgroups among the US population. We found that MASLD was far more common than MetALD and ALD, but all subgroups shared cardiometabolic risk factors. The ALD subgroup has the worst survival, pointing to the synergistic effect of alcohol and metabolic dysfunction. In addition, the SAFE (Steatosis-associated Fibrosis Estimator) score might be a useful non-invasive test to stratify long-term risk in all three SLD subgroups.

背景& 目的最近推出了脂肪性肝病(SLD)的新命名方法,其中包括代谢功能障碍相关SLD(MASLD)、酒精摄入增加相关SLD(MetALD)和酒精相关肝病(ALD)等亚类。在此,我们旨在评估与这些亚组相关的特征和长期预后,以及非侵入性生物标志物的效用。方法利用 NHANES III(第三次全国健康与营养调查)和相关死亡率数据,纳入所有具有可用超声肝脏脂肪变性状态的成年参与者。排除了那些患有病毒性肝炎、饮酒数据不完整、心血管代谢风险以及数据缺失而影响脂肪变性相关纤维化估算器(SAFE)评分计算的人群。比较了无 SLD(超声检查无脂肪变性)、MASLD、MetALD 和 ALD 患者的特征。结果 共有9939名参与者符合条件,其中64%无SLD,MASLD、MetALD和ALD分别占30%、2.3%和1%。与 MASLD 组相比,MetALD 和 ALD 组中男性比例更高,吸烟者也更活跃。MASLD组的糖尿病发病率高于MetALD组和ALD组。ALD亚组的OS明显低于MASLD组(p = 0.004),但MetALD组则没有(p = 0.165)。SAFE评分分层有意义地区分了所有SLD亚组的OS。MetALD具有MASLD和ALD的共同特征。ALD亚组的OS明显低于MASLD亚组,但MetALD和MASLD之间没有差异。SAFE评分可用于对所有SLD亚组的长期预后进行分层。影响和意义:"脂肪肝(SLD)"是最近引入的一个术语,涵盖三个亚组:影响:"脂肪性肝病(SLD)"是最近引入的一个术语,涵盖三个亚组:MASLD(代谢功能障碍相关性 SLD)、MetALD(酒精摄入增加的 MASLD)和 ALD(酒精相关性肝病)。我们探讨了美国人群中这些亚组的特征和结果。我们发现,MASLD 比 MetALD 和 ALD 更为常见,但所有亚组都有共同的心脏代谢风险因素。ALD 亚组的存活率最差,这表明酒精和代谢功能障碍具有协同作用。此外,SAFE(脂肪变性相关纤维化估计器)评分可能是一种有用的无创检测方法,可对所有三个 SLD 亚组的长期风险进行分层。
{"title":"Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score","authors":"","doi":"10.1016/j.jhepr.2024.101127","DOIUrl":"10.1016/j.jhepr.2024.101127","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><p>The new nomenclature of steatotic liver disease (SLD) was recently launched with sub-classifications of metabolic dysfunction-associated SLD (MASLD), MASLD with increased alcohol intake (MetALD), and alcohol-related liver disease (ALD). Herein, we aimed to evaluate the characteristics and long-term outcomes associated with these subgroups and the utility of non-invasive biomarkers.</p></div><div><h3>Methods</h3><p>Using NHANES III (the third National Health and Nutrition Examination Survey) and linked mortality data, all adult participants with available ultrasonographic liver steatosis status were included. Those with viral hepatitis, incomplete data on alcohol consumption, cardiometabolic risk, and missing data that hindered Steatosis-associated Fibrosis Estimator (SAFE) score calculation were excluded. The characteristics of those without SLD (no steatosis on ultrasound), MASLD, MetALD, and ALD were compared. Overall survival (OS) was determined and SAFE score strata were applied to SLD subgroups.</p></div><div><h3>Results</h3><p>A total of 9,939 participants were eligible; 64% had no SLD, while 30%, 2.3%, and 1% had MASLD, MetALD, and ALD, respectively. A higher proportion of men, as well as active smokers, was observed in the MetALD and ALD groups compared to the MASLD group. Diabetes was more prevalent in the MASLD group than in the MetALD and ALD groups. The ALD subgroup had significantly lower OS than the MASLD group (<em>p</em> = 0.004), but the MetALD did not (<em>p</em> = 0.165). SAFE score strata meaningfully differentiated OS of all SLD subgroups.</p></div><div><h3>Conclusions</h3><p>MASLD accounted for the largest proportion of SLD. MetALD shared the characteristics of both MASLD and ALD. The ALD subgroup had a significantly lower OS than the MASLD subgroup but there was no difference between MetALD and MASLD. The SAFE score can be used to stratify long-term outcomes in all SLD subgroups.</p></div><div><h3>Impact and implications:</h3><p>“Steatotic liver disease (SLD)” is a recently introduced term covering three subgroups: MASLD (metabolic dysfunction-associated SLD), MetALD (MASLD with increased alcohol intake), and ALD (alcohol-related liver disease). We explored the characteristics and outcomes of these subgroups among the US population. We found that MASLD was far more common than MetALD and ALD, but all subgroups shared cardiometabolic risk factors. The ALD subgroup has the worst survival, pointing to the synergistic effect of alcohol and metabolic dysfunction. In addition, the SAFE (Steatosis-associated Fibrosis Estimator) score might be a useful non-invasive test to stratify long-term risk in all three SLD subgroups.</p></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 10","pages":"Article 101127"},"PeriodicalIF":9.5,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589555924001319/pdfft?md5=70fb5f648622f96dd3f315e9fc75d05b&pid=1-s2.0-S2589555924001319-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141278081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to ‘Transplant oncology – Current indications and strategies to advance the field’ [JHEP Reports 6 (2024) 100965] 移植肿瘤学--目前的适应症和推进该领域的战略 "的更正[JHEP Reports 6 (2024) 100965]
IF 9.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.jhepr.2024.101071
Felix J. Krendl , Ruben Bellotti , Gonzalo Sapisochin , Benedikt Schaefer , Herbert Tilg , Stefan Scheidl , Christian Margreiter , Stefan Schneeberger , Rupert Oberhuber , Manuel Maglione
{"title":"Corrigendum to ‘Transplant oncology – Current indications and strategies to advance the field’ [JHEP Reports 6 (2024) 100965]","authors":"Felix J. Krendl ,&nbsp;Ruben Bellotti ,&nbsp;Gonzalo Sapisochin ,&nbsp;Benedikt Schaefer ,&nbsp;Herbert Tilg ,&nbsp;Stefan Scheidl ,&nbsp;Christian Margreiter ,&nbsp;Stefan Schneeberger ,&nbsp;Rupert Oberhuber ,&nbsp;Manuel Maglione","doi":"10.1016/j.jhepr.2024.101071","DOIUrl":"10.1016/j.jhepr.2024.101071","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 6","pages":"Article 101071"},"PeriodicalIF":9.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589555924000752/pdfft?md5=09622a9759fd88794907654dfb975933&pid=1-s2.0-S2589555924000752-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141054258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Board page 编辑委员会页面
IF 9.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-01 DOI: 10.1016/S2589-5559(24)00142-3
{"title":"Editorial Board page","authors":"","doi":"10.1016/S2589-5559(24)00142-3","DOIUrl":"https://doi.org/10.1016/S2589-5559(24)00142-3","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 6","pages":"Article 101138"},"PeriodicalIF":9.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589555924001423/pdfft?md5=634b2073d61f5fd7c79d6cc4a42825c8&pid=1-s2.0-S2589555924001423-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141434550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “O-GlcNAc transferase acts as a critical nutritional node for the control of liver homeostasis” [JHEP Reports 6 [2024] 100878] O-GlcNAc转移酶是控制肝脏平衡的关键营养节点》的更正 [JHEP Reports 6 [2024] 100878]
IF 9.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.jhepr.2024.101076
Paula Ortega-Prieto , Lucia Parlati , Fadila Benhamed , Marion Regnier , Isadora Cavalcante , Mélanie Montabord , Rachel Onifarasoaniaina , Maryline Favier , Natasa Pavlovic , Julie Magusto , Michèle Cauzac , Patrick Pagesy , Jérémie Gautheron , Chantal Desdouets , Sandra Guilmeau , Tarik Issad , Catherine Postic
{"title":"Corrigendum to “O-GlcNAc transferase acts as a critical nutritional node for the control of liver homeostasis” [JHEP Reports 6 [2024] 100878]","authors":"Paula Ortega-Prieto ,&nbsp;Lucia Parlati ,&nbsp;Fadila Benhamed ,&nbsp;Marion Regnier ,&nbsp;Isadora Cavalcante ,&nbsp;Mélanie Montabord ,&nbsp;Rachel Onifarasoaniaina ,&nbsp;Maryline Favier ,&nbsp;Natasa Pavlovic ,&nbsp;Julie Magusto ,&nbsp;Michèle Cauzac ,&nbsp;Patrick Pagesy ,&nbsp;Jérémie Gautheron ,&nbsp;Chantal Desdouets ,&nbsp;Sandra Guilmeau ,&nbsp;Tarik Issad ,&nbsp;Catherine Postic","doi":"10.1016/j.jhepr.2024.101076","DOIUrl":"10.1016/j.jhepr.2024.101076","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 6","pages":"Article 101076"},"PeriodicalIF":9.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589555924000806/pdfft?md5=0045d808b5e263b29936145ecfae7375&pid=1-s2.0-S2589555924000806-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141027829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to: “Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results” [JHEP Reports 5 (2019) 101041] 更正:"内镜下十二指肠粘膜重置术可改善2型糖尿病患者的血糖和肝指数:6个月多中心研究结果》[JHEP Reports 5 (2019) 101041]
IF 9.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.jhepr.2024.101041
Annieke C.G. van Baar , Ulrich Beuers , Kari Wong , Rehan Haidry , Guido Costamagna , Alia Hadefi , Jacques Deviere , Soumitra S. Ghosh , Juan Carlos Lopez-Talavera , Leonardo Rodriguez , Manoel P. Galvao Neto , Arun Sanyal , Jacques J.G.H.M. Bergman
{"title":"Corrigendum to: “Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results” [JHEP Reports 5 (2019) 101041]","authors":"Annieke C.G. van Baar ,&nbsp;Ulrich Beuers ,&nbsp;Kari Wong ,&nbsp;Rehan Haidry ,&nbsp;Guido Costamagna ,&nbsp;Alia Hadefi ,&nbsp;Jacques Deviere ,&nbsp;Soumitra S. Ghosh ,&nbsp;Juan Carlos Lopez-Talavera ,&nbsp;Leonardo Rodriguez ,&nbsp;Manoel P. Galvao Neto ,&nbsp;Arun Sanyal ,&nbsp;Jacques J.G.H.M. Bergman","doi":"10.1016/j.jhepr.2024.101041","DOIUrl":"https://doi.org/10.1016/j.jhepr.2024.101041","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 6","pages":"Article 101041"},"PeriodicalIF":9.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589555924000429/pdfft?md5=5ba742f04071f41423d96a68de5b55ef&pid=1-s2.0-S2589555924000429-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141434487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to ‘B4GALNT1 promotes hepatocellular carcinoma stemness and progression via integrin α2β1-mediated FAK and AKT activation’ (JHEP Reports 5 [2023] 100903) B4GALNT1通过整合素α2β1介导的FAK和AKT活化促进肝细胞癌的干性和进展》的勘误(JHEP Reports 5 [2023] 100903)
IF 9.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.jhepr.2024.101042
Yao Tang , Zhijie Xu , Fuyuan Xu , Juan Ye , Jianxu Chen , Jianzhong He , Yingchun Chen , Chunhui Qi , Hongbin Huang , Ruiyang Liu , Hong Shan , Fei Xiao
{"title":"Erratum to ‘B4GALNT1 promotes hepatocellular carcinoma stemness and progression via integrin α2β1-mediated FAK and AKT activation’ (JHEP Reports 5 [2023] 100903)","authors":"Yao Tang ,&nbsp;Zhijie Xu ,&nbsp;Fuyuan Xu ,&nbsp;Juan Ye ,&nbsp;Jianxu Chen ,&nbsp;Jianzhong He ,&nbsp;Yingchun Chen ,&nbsp;Chunhui Qi ,&nbsp;Hongbin Huang ,&nbsp;Ruiyang Liu ,&nbsp;Hong Shan ,&nbsp;Fei Xiao","doi":"10.1016/j.jhepr.2024.101042","DOIUrl":"10.1016/j.jhepr.2024.101042","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 6","pages":"Article 101042"},"PeriodicalIF":9.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589555924000430/pdfft?md5=70ff5988a97c553668489d2a7395bffc&pid=1-s2.0-S2589555924000430-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140283520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CXCR6+CD69+ CD8+ T cells in ascites are associated with disease severity in patients with cirrhosis 肝硬化患者腹水中的 CXCR6+CD69+ CD8+ T 细胞与病情严重程度有关
IF 8.3 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.jhepr.2024.101074
Christian Niehaus , Sebastian Klein , Benedikt Strunz , Erich Freyer , Benjamin Maasoumy , Heiner Wedemeyer , Niklas K. Björkström , Anke R.M. Kraft , Markus Cornberg

Background & Aims

Patients with advanced cirrhosis often develop hepatic decompensation, which is accompanied by systemic inflammation and may eventually lead to acute-on-chronic liver failure. One important cause of systemic hyperinflammation is a dysregulated overshooting immune response in ascites in the abdominal cavity. In this study, we analyzed the role of CD8+ T cells in the ascites immune compartment.

Methods

Peripheral blood and ascites fluid were collected from 50 patients with decompensated cirrhosis. Phenotype and functional responses of CD8+ T cells were analyzed, and obtained data were compared with each other as well as with healthy controls and patients with compensated cirrhosis.

Results

High-dimensional flow cytometry revealed that CD8+ T cells are abundant in the ascites of patients with cirrhosis and exhibit a chronically activated bystander phenotype with innate-like functions. Indeed, we identified distinct CXCR6+CD69+ clusters of late effector memory CD8+ T cells that were rarely found in blood and correlated with clinical parameters of disease severity. Moreover, this CD8+ T-cell population was hyperresponsive to innate cytokines and exhibited cytokine-mediated bystander activation. Interestingly, the Janus kinase (JAK) inhibitor tofacitinib was able to effectively block bystander-activated CXCR6+CD69+ CD8+ T cells and significantly suppress effector molecule production.

Conclusions

The results indicate that CXCR6+CD69+ CD8+ T cells in ascites are associated with disease severity and may contribute to inflammation in patients with decompensated cirrhosis, suggesting that targeted inhibition of this immune cell subset may be a viable therapeutic option.

Impact and Implications

Patients with advanced cirrhosis often develop hepatic decompensation, which is accompanied by systemic inflammation and eventually leads to acute-on-chronic liver failure. One important cause of systemic hyperinflammation is a dysregulated overshooting immune response in ascites in the abdominal cavity. In this study, we demonstrate that CXCR6+CD69+ CD8+ T cells are abundant in the ascites of patients with cirrhosis, exhibit a chronically activated bystander phenotype, and correlate with clinical parameters of disease severity. Moreover, we show that the Janus kinase (JAK) inhibitor tofacitinib can effectively block these bystander-activated CXCR6+CD69+ CD8+ T cells, suggesting that targeted inhibition of this immune cell subset may be a potential therapeutic strategy.

Clinical trial number

Prospective registry: INFEKTA (DRKS00010664).

背景& 目的晚期肝硬化患者常常会出现肝功能失代偿,并伴有全身炎症,最终可能导致急性-慢性肝功能衰竭。全身性高炎症的一个重要原因是腹腔腹水中失调的免疫反应。在这项研究中,我们分析了 CD8+ T 细胞在腹水免疫区的作用。分析了 CD8+ T 细胞的表型和功能反应,并将获得的数据与健康对照组和代偿期肝硬化患者的数据进行了比较。结果 高维流式细胞术显示,CD8+ T 细胞在肝硬化患者的腹水中含量丰富,并表现出具有类似先天性功能的慢性激活旁观者表型。事实上,我们发现了不同的 CXCR6+CD69+ 晚期效应记忆 CD8+ T 细胞群,这些细胞在血液中很少发现,而且与疾病严重程度的临床参数相关。此外,这种 CD8+ T 细胞群对先天性细胞因子反应过度,并表现出细胞因子介导的旁观者活化。有趣的是,Janus 激酶(JAK)抑制剂托法替尼能有效阻断旁观者活化的 CXCR6+CD69+ CD8+ T 细胞,并显著抑制效应分子的产生。结论研究结果表明,腹水中的 CXCR6+CD69+ CD8+ T 细胞与肝硬化失代偿期患者的疾病严重程度有关,并可能导致炎症,这表明靶向抑制该免疫细胞亚群可能是一种可行的治疗方案。影响和意义晚期肝硬化患者通常会出现肝功能失代偿,并伴有全身性炎症,最终导致急性-慢性肝功能衰竭。全身性高炎症的一个重要原因是腹腔腹水中失调的过冲免疫反应。在这项研究中,我们证明 CXCR6+CD69+ CD8+ T 细胞在肝硬化患者腹水中含量丰富,表现出慢性激活的旁观者表型,并与疾病严重程度的临床参数相关。此外,我们还发现Janus激酶(JAK)抑制剂托法替尼能有效阻断这些由旁观者激活的CXCR6+CD69+ CD8+ T细胞,这表明靶向抑制这一免疫细胞亚群可能是一种潜在的治疗策略:Infekta (DRKS00010664)。
{"title":"CXCR6+CD69+ CD8+ T cells in ascites are associated with disease severity in patients with cirrhosis","authors":"Christian Niehaus ,&nbsp;Sebastian Klein ,&nbsp;Benedikt Strunz ,&nbsp;Erich Freyer ,&nbsp;Benjamin Maasoumy ,&nbsp;Heiner Wedemeyer ,&nbsp;Niklas K. Björkström ,&nbsp;Anke R.M. Kraft ,&nbsp;Markus Cornberg","doi":"10.1016/j.jhepr.2024.101074","DOIUrl":"10.1016/j.jhepr.2024.101074","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><p>Patients with advanced cirrhosis often develop hepatic decompensation, which is accompanied by systemic inflammation and may eventually lead to acute-on-chronic liver failure. One important cause of systemic hyperinflammation is a dysregulated overshooting immune response in ascites in the abdominal cavity. In this study, we analyzed the role of CD8<sup>+</sup> T cells in the ascites immune compartment.</p></div><div><h3>Methods</h3><p>Peripheral blood and ascites fluid were collected from 50 patients with decompensated cirrhosis. Phenotype and functional responses of CD8<sup>+</sup> T cells were analyzed, and obtained data were compared with each other as well as with healthy controls and patients with compensated cirrhosis.</p></div><div><h3>Results</h3><p>High-dimensional flow cytometry revealed that CD8<sup>+</sup> T cells are abundant in the ascites of patients with cirrhosis and exhibit a chronically activated bystander phenotype with innate-like functions. Indeed, we identified distinct CXCR6<sup>+</sup>CD69<sup>+</sup> clusters of late effector memory CD8<sup>+</sup> T cells that were rarely found in blood and correlated with clinical parameters of disease severity. Moreover, this CD8<sup>+</sup> T-cell population was hyperresponsive to innate cytokines and exhibited cytokine-mediated bystander activation. Interestingly, the Janus kinase (JAK) inhibitor tofacitinib was able to effectively block bystander-activated CXCR6<sup>+</sup>CD69<sup>+</sup> CD8<sup>+</sup> T cells and significantly suppress effector molecule production.</p></div><div><h3>Conclusions</h3><p>The results indicate that CXCR6<sup>+</sup>CD69<sup>+</sup> CD8<sup>+</sup> T cells in ascites are associated with disease severity and may contribute to inflammation in patients with decompensated cirrhosis, suggesting that targeted inhibition of this immune cell subset may be a viable therapeutic option.</p></div><div><h3>Impact and Implications</h3><p>Patients with advanced cirrhosis often develop hepatic decompensation, which is accompanied by systemic inflammation and eventually leads to acute-on-chronic liver failure. One important cause of systemic hyperinflammation is a dysregulated overshooting immune response in ascites in the abdominal cavity. In this study, we demonstrate that CXCR6<sup>+</sup>CD69<sup>+</sup> CD8<sup>+</sup> T cells are abundant in the ascites of patients with cirrhosis, exhibit a chronically activated bystander phenotype, and correlate with clinical parameters of disease severity. Moreover, we show that the Janus kinase (JAK) inhibitor tofacitinib can effectively block these bystander-activated CXCR6<sup>+</sup>CD69<sup>+</sup> CD8<sup>+</sup> T cells, suggesting that targeted inhibition of this immune cell subset may be a potential therapeutic strategy.</p></div><div><h3>Clinical trial number</h3><p>Prospective registry: INFEKTA (DRKS00010664).</p></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 6","pages":"Article 101074"},"PeriodicalIF":8.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589555924000788/pdfft?md5=214eb9bc97e0176e3ecc27623e229962&pid=1-s2.0-S2589555924000788-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140405449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to ‘Predicting post-resection recurrence by integrating imaging-based surrogates of distinct vascular patterns of hepatocellular carcinoma’ (JHEP Reports 5 [2023] 100806) 通过整合肝细胞癌不同血管模式的成像替代物预测切除术后复发》(JHEP Reports 5 [2023] 100806)的更正
IF 9.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.jhepr.2024.101059
Xiang-Pan Meng , Tian-Yu Tang , Yongping Zhou , Cong Xia , Tianyi Xia , Yibing Shi , Xueying Long , Yun Liang , Wenbo Xiao , Yuan-Cheng Wang , Xiangming Fang , Shenghong Ju
{"title":"Corrigendum to ‘Predicting post-resection recurrence by integrating imaging-based surrogates of distinct vascular patterns of hepatocellular carcinoma’ (JHEP Reports 5 [2023] 100806)","authors":"Xiang-Pan Meng ,&nbsp;Tian-Yu Tang ,&nbsp;Yongping Zhou ,&nbsp;Cong Xia ,&nbsp;Tianyi Xia ,&nbsp;Yibing Shi ,&nbsp;Xueying Long ,&nbsp;Yun Liang ,&nbsp;Wenbo Xiao ,&nbsp;Yuan-Cheng Wang ,&nbsp;Xiangming Fang ,&nbsp;Shenghong Ju","doi":"10.1016/j.jhepr.2024.101059","DOIUrl":"10.1016/j.jhepr.2024.101059","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 6","pages":"Article 101059"},"PeriodicalIF":9.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589555924000600/pdfft?md5=253814cdd3f48c4423bb92186d9466cb&pid=1-s2.0-S2589555924000600-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140275062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to “Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis” [JHEP Reports 6 (2024) 100949] 关于 "进行性家族性肝内胆汁淤积症诊断和治疗的意见书 "的勘误 [JHEP Reports 6 (2024) 100949]
IF 9.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.jhepr.2024.101058
Patrick McKiernan , Jesus Quintero Bernabeu , Muriel Girard , Giuseppe Indolfi , Eberhard Lurz , Palak Trivedi
{"title":"Erratum to “Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis” [JHEP Reports 6 (2024) 100949]","authors":"Patrick McKiernan ,&nbsp;Jesus Quintero Bernabeu ,&nbsp;Muriel Girard ,&nbsp;Giuseppe Indolfi ,&nbsp;Eberhard Lurz ,&nbsp;Palak Trivedi","doi":"10.1016/j.jhepr.2024.101058","DOIUrl":"10.1016/j.jhepr.2024.101058","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 6","pages":"Article 101058"},"PeriodicalIF":9.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589555924000594/pdfft?md5=6078312bb3017debc82330560409a34a&pid=1-s2.0-S2589555924000594-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140278446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum Regarding Previously Published Articles 关于以前发表的文章的勘误
IF 9.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.jhepr.2024.101096
{"title":"Erratum Regarding Previously Published Articles","authors":"","doi":"10.1016/j.jhepr.2024.101096","DOIUrl":"https://doi.org/10.1016/j.jhepr.2024.101096","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 6","pages":"Article 101096"},"PeriodicalIF":9.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589555924001009/pdfft?md5=83a794258a0d23fdd9c710d1e69ac758&pid=1-s2.0-S2589555924001009-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141434253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JHEP Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1